Shield Therapeutics +$0 +0% Wednesday 20:00
1D 1W 1M 3M 1Y 5Y
4 Sep Expected
This list is based on the watchlists of people on Stock Events who follow SHIEF. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Amgen develops treatments in areas similar to Shield Therapeutics, including anemia which directly competes with Shield's Feraccru/Iron product.
AbbVie competes in the pharmaceutical space with products that could serve as alternatives to treatments offered by Shield Therapeutics, especially in gastrointestinal and chronic conditions. Astrazeneca
AZN
Mkt Cap 271.67B
AstraZeneca operates in similar therapeutic areas as Shield, including treatments for anemia and other conditions that Shield's products address. Johnson & Johnson
JNJ
Mkt Cap 399.26B
Johnson & Johnson, through its pharmaceutical division Janssen, offers a wide range of products that compete across the board with Shield's portfolio, including anemia and chronic disease treatments.
GlaxoSmithKline has a broad portfolio that includes treatments for conditions like anemia, competing with Shield's main product offerings.
Pfizer has a diverse drug portfolio that includes treatments in areas competing with Shield Therapeutics, particularly in chronic diseases and conditions treated by Shield's products. Novartis
NVS
Mkt Cap 244.75B
Novartis offers a wide range of pharmaceutical products, including those for anemia and chronic conditions, directly competing with Shield Therapeutics' market. Bristol-Myers Squibb
BMY
Mkt Cap 101.27B
Bristol Myers Squibb competes in the global pharmaceutical market with a focus on serious diseases, including areas that overlap with Shield Therapeutics' focus areas.
Merck operates in various therapeutic areas, including those that compete with Shield Therapeutics, offering alternative treatments for conditions like anemia.
Sanofi produces a range of pharmaceutical products that compete with Shield Therapeutics, especially in the chronic disease treatment space. Health Technology
Pharmaceuticals: Major
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Show more...